| scholarly article | Q13442814 |
| P2093 | author name string | J W Mellors | |
| R J Debs | |||
| J L Ryan | |||
| P2860 | cites work | Treatment of central nervous system toxoplasmosis with pyrimethamine/sulfadiazine combination in 35 patients with the acquired immunodeficiency syndrome. Efficacy of long-term continuous therapy | Q48134771 |
| Expression of human immune interferon cDNA in E. coli and monkey cells | Q48405865 | ||
| In vivo recombinant interleukin 2 administration enhances survival against a lethal challenge with Toxoplasma gondii | Q48432462 | ||
| Modulation of the biological activity of bacterial endotoxin by incorporation into liposomes | Q50201416 | ||
| Enhancement of macrophage Fc-dependent phagocytosis by resident thymocytes: effect of a unique heat-stable lymphokine | Q53923826 | ||
| In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes. | Q54408434 | ||
| Inhibition of lymphokine-induced macrophage microbicidal activity against Leishmania major by liposomes: characterization of the physicochemical requirements for liposome inhibition | Q69594122 | ||
| Intracellular activation of human and rodent macrophages by human lymphokines encapsulated in liposomes | Q69940948 | ||
| Efficient activation of human blood monocytes to a tumoricidal state by liposomes containing human recombinant gamma interferon | Q69942403 | ||
| Protection of mice against fatal herpes simplex type 2 infection by liposomes containing muramyl tripeptide | Q70081994 | ||
| Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy | Q70290545 | ||
| Stimulation of macrophage H2O2 release by resident thymocytes: effect of a soluble factor distinct from interferon-gamma | Q70369724 | ||
| Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells | Q70477478 | ||
| In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes | Q70722545 | ||
| Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines | Q71224610 | ||
| Protein measurement with the Folin phenol reagent | Q20900776 | ||
| Phosphorus assay in column chromatography | Q29614973 | ||
| Assessment of therapy for toxoplasma encephalitis. The TE Study Group | Q33454020 | ||
| Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines | Q33821903 | ||
| Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide | Q35328700 | ||
| Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan | Q36254619 | ||
| Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation | Q36344298 | ||
| Therapy of leishmaniasis: Superior efficacies of liposome-encapsulated drugs | Q37589185 | ||
| Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor | Q37689843 | ||
| Lymphokines | Q38178601 | ||
| Specific Labeling of IntracellularToxoplasma gondiiwith Uracil* | Q39169495 | ||
| Characterization of the effects of endotoxin on macrophage tumor cell killing | Q39201093 | ||
| AIDS commentary. Toxoplasmic encephalitis | Q39599369 | ||
| Interferon-gamma, the activated macrophage, and host defense against microbial challenge | Q39601454 | ||
| Current concepts: immunology. Monocytes and macrophages | Q39631972 | ||
| Liposomes as carriers of antimicrobial agents | Q39661451 | ||
| Liposome targeting to macrophages: opportunities for treatment of infectious diseases | Q39750586 | ||
| Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. | Q40805694 | ||
| Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma | Q40806269 | ||
| Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion | Q40808703 | ||
| Cerebral toxoplasmosis complicating the acquired immune deficiency syndrome: clinical and neuropathological findings in 27 patients | Q40809711 | ||
| Phase I trial of recombinant interferon gamma in cancer patients | Q40810991 | ||
| Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study | Q40818917 | ||
| Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes | Q41486954 | ||
| Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes | Q44328218 | ||
| A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture | Q46634011 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | macrophage | Q184204 |
| P304 | page(s) | 132-137 | |
| P577 | publication date | 1989-01-01 | |
| P1433 | published in | Infection and Immunity | Q6029193 |
| P1476 | title | Incorporation of recombinant gamma interferon into liposomes enhances its ability to induce peritoneal macrophage antitoxoplasma activity | |
| P478 | volume | 57 |
| Q33746997 | Comparison of mutants of Toxoplasma gondii selected for resistance to azithromycin, spiramycin, or clindamycin |
| Q40507955 | Liposomes as delivery systems in the prevention and treatment of infectious diseases |
| Q39287046 | Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications. |
| Q35836436 | Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant |
| Q54264731 | Respiratory burst capacity of activated macrophages is resistant to depression by erythrocyte phagocytosis. |
| Q37346988 | Role of gamma interferon in Toxoplasma gondii infection |
Search more.